887.8000 17.55 (2.02%)
NSE Jul 11, 2025 15:31 PM
Volume: 428.1K
 

logo
Strides Pharma Science Ltd.
11 Feb 2018, 12:00AM
887.80
2.02%
Motilal Oswal
We reduce our sales estimates by 25%/29%/28% and PAT estimates by 61%/35%/28% for FY18/19/20 to factor (1) demerger of commodity API business, (2) lower than expected operating margin in3QFY18, and (3) delay in procurement with respect to institutional business.There is a risk of increased price erosion in recently-launched molecules;however pipeline remains robust for better growth, subject to approval. We value STR on sum-of-the-parts (SOTP), valuing the p harma business at 18x12M forward earnings (industry average P/E multiple for midcap pharma)and Solara at an EV of 8x (from 12x earlier to factor commodity nature of API business) FY19E EBITDA to arrive at a price target of INR989. Reiterate Buy
Promoters unpledged 2.27% of shares in last quarter. Total pledge stands at 51.98% of promoter holdings
More from Strides Pharma Science Ltd.
Recommended